NCT05007769View on ClinicalTrials.gov

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung CancerNon-small Cell CarcinomaNSCLCNon Small Cell Lung Cancer
Interventions
DRUG

Ramucirumab

Will be supplied by Lilly Oncology, free of charge to the participant

DRUG

Atezolizumab

Atezolizumab will be commercially available.

DRUG

N-803

Will be supplied free of charge to the participants by ImmunityBio

Sponsors

Collaborators (1)

ImmunityBio, Inc.
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

ImmunityBio, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT05007769 - Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | Biotech Hunter | Biotech Hunter